Pamplona, Spain

Xabier Aguirre Ena

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Xabier Aguirre Ena: Innovator in Cancer Treatment

Introduction

Xabier Aguirre Ena is a prominent inventor based in Pamplona, Spain. He has made significant contributions to the field of medical research, particularly in the development of compounds that target DNA methyltransferases and histone methyltransferases. His work is crucial in the fight against cancer and other diseases.

Latest Patents

Xabier Aguirre Ena holds two notable patents. The first patent is titled "Compounds as inhibitors of DNA methyltransferases." This invention relates to compounds that serve as inhibitors of DNMT1, DNMT3A, and DNMT3B, which are essential in the treatment and prevention of cancer, fibrosis, and immunomodulation. The second patent is "Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases." This patent focuses on compounds that act as anticancer agents and facilitate the generation of induced pluripotent stem cells.

Career Highlights

Throughout his career, Xabier has worked with esteemed organizations such as Fundación para la Investigación Médica Aplicada. His research has led to advancements in pharmaceutical and veterinary compositions that utilize his patented compounds.

Collaborations

Xabier has collaborated with notable colleagues, including Julen Oyarzabal Santamarina and Felipe Prósper Cardoso. These partnerships have enhanced the impact of his research and innovations in the medical field.

Conclusion

Xabier Aguirre Ena is a distinguished inventor whose work in developing innovative compounds has the potential to revolutionize cancer treatment. His contributions to medical research continue to pave the way for new therapeutic approaches.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…